We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Teva To Sue FDA Over Pravachol Marketing Exclusivity

Law360 (July 6, 2005, 12:00 AM EDT) -- Israeli drug maker Teva Pharmaceutical Industries Ltd. said Wednesday it would sue the U.S. Food and Drug Administration over a decision that effectively wiped out the company’s marketing exclusivity for a generic version of Bristol-Myers Squibb Co.'s cholesterol medication Pravachol.

Teva said it strongly disagreed with the FDA ruling, which determined that the 180-day exclusivity period for generic versions Pravachol began on August 22, when another generic drug maker's lawsuit against Bristol-Myers was dismissed.

In that case, Canadian drug maker Apotex Inc. had sought a declaratory...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.